Business
Piper Sandler Companies Elects Stuart M. Essig to Board of Directors
MINNEAPOLIS, February 04, 2026--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of Stuart M. Essig, Ph.D. to its board of directors.
About this update from Piper Sandler Companies
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/932b2c55d9bf885323ed3058e389e789"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/em3wY_0wWbs.6Tgd.f5KfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/932b2c55d9bf885323ed3058e389e789","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/izPVEqiddWYqXabewbYp8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/932b2c55d9bf885323ed3058e389e789","width":1024,"height":512}},"lazy":false},{"type":"text","content":"MINNEAPOLIS, February 04, 2026--(BUSINESS WIRE)--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of Stuart M. Essig, Ph.D. to its board of directors.","length":202,"tagName":"p"},{"type":"text","content":""Stuart will be a great asset to our board of directors. He brings deep experience and knowledge of the healthcare and medical technology industries, which remain important sectors for our investment banking business. In addition, his proven track record of leading a growing, publicly traded company will provide valuable perspective to the board," said Chad Abraham, Piper Sandler chairman and chief executive officer.","length":430,"tagName":"p"},{"type":"text","content":"Essig previously served as chief executive officer and director of Integra LifeSciences Corporation, a global medical technology company focused on innovative solutions for neurosurgery, tissue reconstruction, and advanced wound care, from 1997 to 2012. Following that, he has served as chairman from 2012 until today and executive chairman during 2024 and 2025. During Essig’s tenure, Integra LifeSciences grew revenues from approximately $15 million to more than $1.6 billion. Before joining Integra, Essig was a managing director in the healthcare group at Goldman Sachs where he had 10 years of experience, serving as a senior mergers and acquisitions advisor to a broad range of domestic and international medical technology, pharmaceutical and biotechnology clients.","length":772,"tagName":"p"},{"type":"text","content":"In addition to serving as chairman of Integra, Essig c...